BG104368A - Нови полиморфни форми на ципамфилин - Google Patents

Нови полиморфни форми на ципамфилин

Info

Publication number
BG104368A
BG104368A BG104368A BG10436800A BG104368A BG 104368 A BG104368 A BG 104368A BG 104368 A BG104368 A BG 104368A BG 10436800 A BG10436800 A BG 10436800A BG 104368 A BG104368 A BG 104368A
Authority
BG
Bulgaria
Prior art keywords
cipamfylline
polymorphic forms
novel polymorphic
forms
novel
Prior art date
Application number
BG104368A
Other languages
English (en)
Inventor
Drake Eggleston
Ian R. Lynch
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Smithkline Beecham P.L.C. filed Critical Smithkline Beecham Corporation
Publication of BG104368A publication Critical patent/BG104368A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG104368A 1997-10-23 2000-04-21 Нови полиморфни форми на ципамфилин BG104368A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6323897P 1997-10-23 1997-10-23
PCT/US1998/022451 WO1999020625A1 (en) 1997-10-23 1998-10-23 Novel polymorphic forms of cipamfylline

Publications (1)

Publication Number Publication Date
BG104368A true BG104368A (bg) 2001-02-28

Family

ID=22047900

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104368A BG104368A (bg) 1997-10-23 2000-04-21 Нови полиморфни форми на ципамфилин

Country Status (28)

Country Link
US (2) US6583283B1 (bg)
EP (1) EP1025103A4 (bg)
JP (1) JP2001520228A (bg)
KR (1) KR20010031246A (bg)
CN (1) CN1280579A (bg)
AP (1) AP2000001793A0 (bg)
AR (1) AR015190A1 (bg)
AU (1) AU751561B2 (bg)
BG (1) BG104368A (bg)
BR (1) BR9814099A (bg)
CA (1) CA2306980A1 (bg)
CO (1) CO4990930A1 (bg)
DZ (1) DZ2629A1 (bg)
EA (1) EA003445B1 (bg)
HU (1) HUP0100019A3 (bg)
ID (1) ID23885A (bg)
IL (1) IL135711A0 (bg)
MA (1) MA24682A1 (bg)
NO (1) NO20002012L (bg)
NZ (1) NZ504051A (bg)
PE (1) PE122599A1 (bg)
PL (1) PL340257A1 (bg)
SA (1) SA99191117A (bg)
SK (1) SK5642000A3 (bg)
TR (1) TR200001109T2 (bg)
UY (2) UY25220A1 (bg)
WO (1) WO1999020625A1 (bg)
ZA (1) ZA989622B (bg)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200300622A1 (ru) 2001-01-31 2003-12-25 Пфайзер Продактс Инк. Производные амидов тиазолил-, оксазолил, пирролил- и имидазолилкислот, полезные в качестве ингибиторов изоферментов pde4
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
OA12541A (en) 2001-01-31 2006-06-05 Pfizer Prod Inc Ether derivatives useful as inhibitors of PDE4 isozymes.
NZ526453A (en) 2001-01-31 2005-01-28 Pfizer Prod Inc Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
DE60319980T2 (de) 2002-05-31 2009-04-16 Schering Corporation Xanthin-phosphodiesterase-v-hemmer polymorphe
CN101031293A (zh) 2004-05-06 2007-09-05 普莱希科公司 Pde4b抑制剂及其应用
CN101048407A (zh) 2004-09-03 2007-10-03 普莱希科公司 双环杂芳基pde4b抑制剂
JP5119153B2 (ja) * 2005-09-20 2013-01-16 シノファーム シンガポール ピーティーイー,リミテッド イリノテカン塩酸塩の新規結晶形

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
PL340257A1 (en) 2001-01-29
SA99191117A (ar) 2005-12-03
MA24682A1 (fr) 1999-07-01
ID23885A (id) 2000-05-25
DZ2629A1 (fr) 2003-03-08
AP2000001793A0 (en) 2000-06-30
IL135711A0 (en) 2001-05-20
EP1025103A1 (en) 2000-08-09
UY25220A1 (es) 2001-08-27
AU751561B2 (en) 2002-08-22
NO20002012D0 (no) 2000-04-17
EA003445B1 (ru) 2003-06-26
CN1280579A (zh) 2001-01-17
PE122599A1 (es) 2000-02-12
TR200001109T2 (tr) 2000-09-21
ZA989622B (en) 1999-04-23
EP1025103A4 (en) 2001-11-14
UY25380A1 (es) 1999-11-17
EA200000448A1 (ru) 2000-10-30
SK5642000A3 (en) 2000-09-12
NZ504051A (en) 2003-02-28
AR015190A1 (es) 2001-04-18
US6583283B1 (en) 2003-06-24
HUP0100019A3 (en) 2003-01-28
JP2001520228A (ja) 2001-10-30
CO4990930A1 (es) 2000-12-26
HUP0100019A2 (hu) 2002-01-28
WO1999020625A1 (en) 1999-04-29
US20020173648A1 (en) 2002-11-21
NO20002012L (no) 2000-04-17
CA2306980A1 (en) 1999-04-29
KR20010031246A (ko) 2001-04-16
BR9814099A (pt) 2000-10-10
AU1274499A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
AU2160492A (en) Treatment of human diseases involving dysregulation or dysfunction of the nervous system
NZ335992A (en) Substituted pyrimidinone and pyridone compounds and methods of use
YU45204A (sh) 3-BETA-D-RIBOFURANOZILTIAZOLO/4,5-d/ PIRIMIDINSKI NUKLEOZIDII NJIHOVA UPOTREBA
CA2269815A1 (en) Thienopyrimidines having pde v-inhibiting action
WO1998024782A3 (en) Substituted pyrimidine compounds and their use
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
AU2002327378A1 (en) Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
WO2003041643A3 (en) Hsp90-inhibiting zearalanol compounds and methods of producing and using same
AU2399892A (en) Treatment of anxiety disorders by nerve stimulation
NO20002702L (no) Tienopyrimidiner
AU4960297A (en) Bicyclic aryl carboxamides and their therapeutic use
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU2284001A (en) Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
DE50211929D1 (en) Pyrimidinderivate
BG104368A (bg) Нови полиморфни форми на ципамфилин
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
IL150125A0 (en) Novel compounds
ZA984177B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
NO991734L (no) Pyrazolinoner for behandling av potensforstyrrelser
MXPA02012260A (es) 2-aminoalquil-tieno[2,3-d]pirimidinas.
CA2014884A1 (en) 5,11-dihydro-6h-pyrido[2,3-b][1,4]benzodiazepin-6-ones and -thiones and their use in the prevention or treatment of aids
MXPA98005355A (es) Derivados de 5-[(heteroaril) alquil]-3 -oxo-pirido [1, 2-a]bencimidazol -4-carboxamida utiles en el tratamiento de trastornos del sistema nervioso central.
EP0276805A3 (en) Substituted 3-phenyl-7h-thiazoloû3,2-b¨û1,2,4¨triazin-7-ones, processes for their preparation, medicaments containing them and their use as well as some of the intermediates obtained during the preparation of said compounds
WO1999015160A3 (en) Use of 6,7-substituted 2-aminotetralines suitable for preparing pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies